Canada · Delayed Price · Currency is CAD Helix BioPharma Statistics
Total Valuation
Helix BioPharma has a market cap or net worth of CAD 113.80 million. The enterprise value is 114.13 million.
| Market Cap | 113.80M |
| Enterprise Value | 114.13M |
Important Dates
The next estimated earnings date is Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Helix BioPharma has 76.38 million shares outstanding. The number of shares has increased by 46.69% in one year.
| Current Share Class | 76.38M |
| Shares Outstanding | 76.38M |
| Shares Change (YoY) | +46.69% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.44% |
| Owned by Institutions (%) | n/a |
| Float | 54.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.45, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.45 |
| Quick Ratio | 0.43 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -62.67 |
Financial Efficiency
Return on equity (ROE) is -49.99% and return on invested capital (ROIC) is -29.83%.
| Return on Equity (ROE) | -49.99% |
| Return on Assets (ROA) | -18.19% |
| Return on Invested Capital (ROIC) | -29.83% |
| Return on Capital Employed (ROCE) | -22.19% |
| Weighted Average Cost of Capital (WACC) | 2.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -474,857 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.22% in the last 52 weeks. The beta is -0.38, so Helix BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +60.22% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 37.02 |
| Average Volume (20 Days) | 2,046 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.26M |
| Pretax Income | -3.32M |
| Net Income | -3.32M |
| EBITDA | -3.26M |
| EBIT | -3.26M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 2.84 million in cash and 359,000 in debt, with a net cash position of 2.48 million or 0.03 per share.
| Cash & Cash Equivalents | 2.84M |
| Total Debt | 359,000 |
| Net Cash | 2.48M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 14.69M |
| Book Value Per Share | 0.19 |
| Working Capital | -3.70M |
Cash Flow
| Operating Cash Flow | -3.21M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Helix BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.69% |
| Shareholder Yield | -46.69% |
| Earnings Yield | -2.92% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 16, 2024. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |